Morgan Stanley lowers its rating on Teva Pharmaceuticals TEVA to Equal-weight from Overweight while reiterating the price target of $47 a shre, as it believes the company's risk to reward ratio is now more balanced.
Morgan Stanley says, "An improved outlook, $3B share buyback, and new CEO Jeremy Levin have driven Teva's multiple from 7x to ~8x, but we now see the risk-reward as balanced in the context of our relative rating system. ...We and consensus expect Teva to prevail on Copaxone patent litigation. We see $1–$2 stock upside if Teva wins and $5–$6 downside if Teva surprisingly loses."
TEVA closed at $45.71 a share on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in